Is Ibogaine Legal in the United States?
No. Ibogaine is illegal in the United States. It is a Schedule I controlled substance under the federal Controlled Substances Act — the most restrictive category, for drugs the government defines as having a high potential for abuse, no currently accepted medical use, and no accepted safety for use under medical supervision. It is listed by name among Schedule I hallucinogenic substances at 21 CFR 1308.11, under DEA drug code 7260. No doctor in America can prescribe it, no pharmacy can stock it, and no clinic can legally give it to a patient. Outside federally authorised research, possessing, making, selling or importing it is a federal offence in every state.
The plain reality behind the question is a contradiction people can see with their own eyes: the same federal government that classifies ibogaine as a drug with no accepted medical use announced on Thursday that it will spend up to $4.9 million developing it as a treatment. Health Secretary Robert F. Kennedy, Jr. said the money, awarded through the health research agency ARPA-H the day after Veterans Day, will prepare the ground for clinical trials of ibogaine for post-traumatic stress disorder and other serious mental illness, including in veterans — the announcement we reported on the blog today. Kennedy's claim is that the veterans' own testimony settles the need to look: they told his department the treatment changed their lives, and that, he says, demands serious scientific investigation. The law, meanwhile, has not moved an inch — not the April directive from President Trump accelerating psychedelic research, and not Thursday's awards.
"These awards fund the regulatory and manufacturing groundwork for future trials. It does not fund treatment of patients or human-subject research, and it does not authorize clinical trials or establish FDA approval."
That sentence, from the Health Department's own announcement, states the common-sense principle plainly: funding research into a medicine does not make the medicine legal. Only FDA approval of a specific product, and rescheduling by the DEA, can change a Schedule I status — and neither has happened. The consequence is the gap veterans are living in now. A veteran who believes ibogaine can help his PTSD cannot walk into a VA hospital or any American clinic and receive it; the legal clinics veterans travel to are abroad, notably in Mexico, outside American medical oversight. And the risks are not theoretical — the Health Department itself warns ibogaine carries serious safety risks, including potentially life-threatening heart rhythm problems, which is why it says future studies must build in screening, cardiac monitoring and independent safety oversight. If a treatment is promising enough for the government to fund and dangerous enough for the government to warn about, the question that follows is how long the people it is meant to help must leave the country — or break the law — to reach it.
The details of Thursday's announcement show how early this road is. The research teams selected by ARPA-H are led by the Mark Cuban Cost Plus Drug Company, which will build the regulatory, clinical, chemical and engineering foundation for a domestically manufactured ibogaine hydrochloride product, while Beond, Inc. delivers clinical data on safety, dosing and durability; the initial commitment is up to $4.9 million over five years, with further awards expected on substance use disorders. The National Institute of Mental Health separately opened a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs such as ketamine and psilocybin, with recipients to be named in the summer of 2027. Reuters reported that President Trump allocated $50 million in April for ibogaine research. VA Secretary Doug Collins said his department looks forward to preparing its clinicians "to deliver new treatments if they earn FDA approval" — the if on which every part of this now rests. Kennedy closed the announcement with the promise the funding is meant to serve:
"We owe veterans more than promises. We owe them rigorous science, honest answers and a path to affordable care if the evidence supports it."